Influenza Disease Suppliers Serving Saskatchewan

In the late 1940s, Charles B. Kaufmann patented and manufactured the first Nixalite bird control spike models and founded the Nixalite of America, Inc. Company. Almost at once, people could see the endless possibilities that these stainless steel ...

BioDiem is an Australian biopharmaceutical company that is focused on developing and commercialising vaccines and infectious disease therapies. Our business model is to generate income from partnerships including with other vaccine and infectious ...

What we do is driven by what we believe. Which is helping create a better quality of life on a large scale. That’s why we are making our revolutionary PCR technology available at cost-efficient pricing around the world. No matter your geography and ...

Dyadic International, Inc. (NASDAQ: DYAI) is a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein bioproduction and unmet clinical needs for effective, affordable, and ...

ProImmune’s mission is to be your partner of choice for understanding and managing adaptive immune responses. We offer unique solutions for preclinical and clinical immunology research, including a comprehensive and integrated antigen ...

Vitrosens Biotechnology is a high-tech company in Turkey founded for the development, manufacture, and delivery of in vitro diagnostic devices (IVD) to the world. Vitrosens Biotechnology headquartered in Turkey, by a group of entrepreneurs with a ...

Guangzhou Wondfo Biotech Co., Ltd., headquartered in Guangzhou science city, has been focusing on the R&D, production, sales and service of point-of-care testing (POCT) products and providing customers with professional rapid diagnosis and chronic ...

Ellume is a digital diagnostics company that develops, manufactures, and commercializes high-performance, connected products for healthcare professionals and consumers. It is at the forefront of accurate, rapid and accessible testing that is ...

FluGen, Inc. is developing a more effective vaccine in the fight against influenza and respiratory disease. The M2SR Vaccine Platform has the potential to revolutionize the $5 billion annual influenza market, with a clinically-tested vaccine ...